GeneNews (TSX:GEN) is addressing the major issue in earlycancer screening - patient reluctance with inconvenient and intrusive screening methods - with a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early.Read More
3D Signatures (TSX-V:DXD) which has developed proprietary software with the potential to analyze a patient’s chromosomal arrangement, or signature, is seeking collaborations to advance its TeloView platform in the areas of Hodgkin’s lymphoma, prostrate cancer, multiple myeloma and Alzheimer’s disease.Read More
As head of healthcare research and as the senior biotechnology analyst with Maxim Group, Jason Kolbert has worked extensively in the healthcare sector. This includes pharma experience with Schering-Plough in Japan, as a fund manager and as an equity analyst for the past 20 years.Read More
As an advisor and consultant with Cyrex Laboratories, a clinical immunology lab, Dr. Chad Larson holds a Doctor of Naturopathic Medicine degree from Southwest College of Naturopathic Medicine and a Doctor of Chiropractic degree from Southern California University of Health Sciences.Read More
Wael Fayad, who moved into the executive suite of Enumeral (OTCQB:ENUM) as chairman, president and CEO at the end of September, plans to reboot the company in the near term through partnering and collaborations.Read More
Closely-held NeuroproteXeon has received agreement on a special protocol assessment from the FDA for a Phase 3 trial of its inhaled pharmaceutical grade product, XENEX, a xenon gas formulation, as a neuroprotecter against brain cell death following acute neurologic injury, such as cardiac arrest.Read More
With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in the first quarter next year with bladder cancer patients.Read More
As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the U.S., and No. 2 for stock-picking in biotech in 2011. She also received the No. 2 ranking in The Wall Street Journal’s “Best on the Street” listing in 2011. Prior to joining William Blair in 2011, Ms. Xu was a SVP and senior biotech analyst at Wedbush Securities; VP and senior biotech analyst at Credit Suisse; and a senior biotech analyst at Pacific Growth Equities. Before her move into equity research, Ms. Xu worked in investment banking for two years. In this interview with BioTuesdays.com, Ms. Xu discusses her industry-leading research report entitled, Hepatitis B: The Next Frontier, and some of her best investment ideas in the Hep B space.Read More
Mesoblast (NASDAQ:MESO; ASX:MSB) has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.
“This technology has the potential to target advanced stages of diseases, with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions,” CEO and managing director, Dr. Silviu Itescu, says in an interview with BioTuesdays.com.
Dr. Itescu explains Mesoblast’s MLCs are rare cells and central to blood vessel maintenance, repair and regeneration, largely via secretion of growth factors, which act on neighboring endothelial cells to promote blood vessel regeneration and function.Read More
As it transitions from a discovery and technology platform-focused organization to a clinical stage biotech company, Critical Outcome Technologies (OTCQB:COTQF; TSX-V:COT) is approaching a critical inflection point by mid-2017 with its lead program, COTI-2, in in gynaecological cancers.
COTI-2 is currently being evaluated in a Phase 1 clinical study at two premier cancer centers in the U.S.
“We’ve assembled an impressive amount of supportive preclinical data in the past for COTI-2, and are excited to be evaluating in the clinic this potentially significant therapeutic option for women suffering from debilitating gynecological cancers, such as ovarian cancer,” Alison Silva, president, says in an interview with BioTuesdays.com.Read More
In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its pipeline, expanding internationally and investing in life science funds to gain access to new pharmaceuticals.
“Over the next 30 months, we want to get real and demonstrate that we are good at commercializing and selling innovative pharmaceuticals that touch people's lives,” CEO, Jonathan Ross Goodman, says in an interview with BioTuesdays.com.
“In the highly competitive Canadian licensing landscape, we have been more creative and are adding more horsepower to our licensing capabilities,” he adds, noting that all of Knight’s products are sourced through partnerships and acquisitions.Read More
Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus on platinum-resistant ovarian cancer and acute myeloid leukemia.
“VDAs have been around for a long time but we’re taking them in a new direction: in combination with anti-angiogenic (AA) therapies,” president and CEO, Dr. William Schwieterman, says in an interview with BioTuesdays.com.Read More
As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of directors and the lupus research community to bring national attention and resources to lupus research and education. Ms. Raymond came to the LFA after serving as the founding CEO of the National Osteoporosis Foundation, beginning in 1986. She envisions great progress in lupus treatment and care over the next 10 years but recognizes the urgent need to elevate lupus on the national healthcare agenda by increasing federal and private investment in research on lupus and developing constructive public policies aimed at bringing support and services to all people affected by lupus. In this interview with BioTuesdays.com, Ms. Raymond discusses the state of the disease and results of a recent clinical study by Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP).Read More
BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from Canada.
“We’re working on a couple of international deals now,” René Goehrum, chairman, president and CEO, says in an interview with BioTuesdays.com.
Mr. Goehrum explains that BioSyent hopes to commercialize new product deals in the Middle East, Latin America and Southeast Asia. “These products may not be licensed for sale in Canada.”Read More
After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss proceeding with a Phase 3 clinical trial in 2017.
“We believe that our data set shows that oral insulin works, which is a first in history,” Josh Hexter, COO and VP of business development, says in an interview with BioTuesdays.com.
“While currently under development, our Phase 3 program will focus on safety and long-term HbA1c lowering efficacy, and will include both active comparator and placebo controlled trials,” he adds. HbA1c is an important three-month average of plasma glucose concentration in blood.Read More
As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies category and was named the top stock picker in U.S. Health Care Equipment and Supplies in StarMine’s 2013 analyst awards. Prior to joining Feltl, he founded two technology startups – Taggart Communications and Spigot Games – and spent five years in equity trading at RBC Capital Markets, including several years as a NASDAQ market maker. In this interview with BioTuesdays.com, Mr. Haynor discusses industry trends in medical devices and a couple of his favorite investment ideas.Read More
Closely-held Parvus Therapeutics is developing a broad therapeutic platform, called Navacims, to treat autoimmune diseases through in vivo expansion and activation of disease-specific regulatory T-cells (T-regs), which normally play a key role in maintaining immune system balance and immune tolerance.
“We have extensive preclinical proof-of-concept data, with in vivo reversal of disease in mouse models of Type 1 diabetes, multiple sclerosis and rheumatoid arthritis,” CEO, Janice LeCocq, says in an interview with BioTuesdays.com.
“Furthermore, our extensive animal safety studies have shown no off-target affects, no general immune suppression and no cytokine release syndrome,” she adds. “Navacims are designed to halt the disease without negatively affecting the body’s normal immune functions.”Read More
Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs).
“TACs were designed to use the natural activation and inhibitory pathways of T cells and have the potential to outperform identically-directed chimeric antigen receptor (CAR) T cells,” president and CEO, Dr. Tony Fiorino, says in an interview with BioTuesdays.com.Read More
As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides fast and inexpensive sample-to-result DNA testing. One-in-three people carry genetic mutations and carrying a CYP2C19 mutation can impair drug metabolism. Some 15% of all prescribed drugs are metabolized by CYP2C19 enzymes, including anti-platelet drugs, anti-depressants and proton pump inhibitors. In May, the company introduced the Spartan Cube, the world’s smallest commercial molecular diagnostics device that enables unprecedented portability and convenience. In this interview with BioTuesdays.com, Dr. Lem discusses the thinking behind the Spartan Cube, its benefits and potential for home use.Read More